Search results for "Randomized"

showing 10 items of 2323 documents

Epidemiology, prevention and screening for prostate cancer.

1996

Prostate cancer is a growing social problem. The economical impact is high and is likely to become greater in future years, not only because the number of patients diagnosed with prostatic neoplasias is increasing steadily, but also because of the promotion of screening programmes and the rise in the number of surgical procedures available. It can be concluded that, at the present stage, widespread implementation of screening cannot be recommended. The answer to the question of screening can only be provided by large randomised trials, comparing either screening versus no screening, or early versus delayed treatment in patients in whom early cancer is detected by screening.

Malemedicine.medical_specialtyEarly cancerUrologyCost-Benefit AnalysisRisk AssessmentProstate cancerEpidemiologymedicineHumansMass ScreeningIn patientStage (cooking)Intensive care medicineRandomized Controlled Trials as TopicPalpationbusiness.industryRectumProstatic NeoplasmsDelayed treatmentSurgical proceduresMiddle AgedProstate-Specific Antigenmedicine.diseasePrimary PreventionPhysical therapybusinessEuropean urology
researchProduct

The treatment of venous leg ulcers: a new therapeutic use of iloprost

2007

Background: We conducted a study using an intravenous (i.v.) infusion of iloprost in the treatment of venous ulcers to verify whether the association of i.v. iloprost + local therapy + elastic compression has a favorable effect when compared with traditional treatment with local therapy and elastic compression. Study Design: We evaluated the effects of iloprost in 98 consecutive patients with noncomplicated venous ulcers of lower limbs subdivided into 2 groups: the first group (48 patients) received iloprost in saline solution for 3 weeks and the second group (50 patients) received a venous infusion of a saline solution. The patients were examined at baseline time 0 (first visit) and then a…

Malemedicine.medical_specialtyElastic compressionmedicine.medical_treatmentIschemiaPlacebo groupDrug Administration Schedulelaw.inventionRandomized controlled triallawmedicineHumansSingle-Blind MethodIloprostInfusions IntravenousVeinSalineDose-Response Relationship Drugbusiness.industryvenous ulcersiloprostLeg UlcerSignificant differenceMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureDebridementAnesthesiaAnti-Infective Agents LocalFemaleSurgeryVENOUS LEG ULCERS ILOPROSTbusinessPlatelet Aggregation InhibitorsStockings CompressionIloprostmedicine.drug
researchProduct

Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered sep…

2003

The safety and reactogenicity of a booster dose of GSK Biologicals' hexavalent DTPa-HBV-IPV/Hib vaccine (N=4725) was compared with the separate administration of GSK Biologicals' DTPa-IPV/Hib and HBV vaccines (N=4474) in two open, randomized multicenter studies (A and B). Solicited symptoms occurring within 4 days of vaccination were recorded on diary cards and serious adverse events (SAEs) were collected throughout the study period. In Study A (N=1149), incidences of solicited symptoms were similar in both groups; there were no SAEs either reported within 4 days of vaccination or considered to be causally related to vaccination. In study B (N=8050), where fever was the only solicited sympt…

Malemedicine.medical_specialtyFeverImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesInternal medicineConfidence IntervalsHumansMulticenter Studies as TopicMedicineHepatitis B VaccinesVaccines CombinedAdverse effectDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicHepatitis B virusBooster (rocketry)ReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunizationImmunologyMolecular MedicineFemalebusinessVaccine
researchProduct

Effectiveness of a transdiagnostic internet-based protocol for the treatment of emotional disorders versus treatment as usual in specialized care: st…

2015

Emotional disorders (depression and anxiety disorders) are highly prevalent mental health problems. Although evidence showing the effectiveness of disorder-specific treatments exists, high comorbidity rates among emotional disorders limit the utility of these protocols. This has led some researchers to focus their interest on transdiagnostic interventions, a treatment perspective that might be more widely effective across these disorders. Also, the current way of delivering treatments makes it difficult provide assistance to all of the population in need. The use of the Internet in the delivery of evidence-based treatments may help to disseminate treatments among the population. In this stu…

Malemedicine.medical_specialtyGeneralized anxiety disorderTime FactorsEmotionsPsychological interventionMedicine (miscellaneous)AnxietyStudy ProtocolClinical ProtocolsSurveys and QuestionnairesmedicineHumansPharmacology (medical)PsychiatryComputer-delivered psychotherapyPsychiatric Status Rating ScalesTransdiagnosticExtraversion/behavioral activationDepressive DisorderInternetbusiness.industryDepressionPanic disorderSocial anxietyEmotional disordersmedicine.diseaseNeuroticism/behavioral inhibitionNeuroticismAnxiety DisordersIntention to Treat AnalysisPsychotherapyTreatment OutcomePatient SatisfactionResearch DesignSpainRandomized controlled trialTherapy Computer-AssistedQuality of LifeAnxietyFemalemedicine.symptombusinessDelivery of Health CareAnxiety disorderAgoraphobiaClinical psychologyTrials
researchProduct

Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Respons…

2015

UNLABELLED Although sofosbuvir has been approved for patients with genotypes 2/3 (G2/3), many parts of the world still consider pegylated Interferon alpha (P) and ribavirin (R) as standard of care for G2/3. Patients with rapid virological response (RVR) show response rates >80%. However, SVR (sustained virological response) in non-RVR patients is not satisfactory. Longer treatment duration may be required but evidence from prospective trials are lacking. A total of 1006 chronic HCV genotype 2/3 patients treated with P/R were recruited into a German HepNet multicenter screening registry. Of those, only 226 patients were still HCV RNA positive at week 4 (non-RVR). Non-RVR patients with ongoin…

Malemedicine.medical_specialtyGenotypeSofosbuvirlcsh:MedicineAlpha interferonHepaciviruslaw.inventionchemistry.chemical_compoundRandomized controlled trialRecurrencelawPegylated interferonSurveys and QuestionnairesInternal medicineRibavirinClinical endpointmedicineHumansProspective Studiesddc:610lcsh:ScienceProspective cohort studyMultidisciplinarybusiness.industryRibavirinlcsh:RInterferon-alphaHepatitis C ChronicMiddle AgedSurgeryClinical trialLogistic ModelsTreatment OutcomechemistryMultivariate AnalysisFemalelcsh:QbusinessResearch Articlemedicine.drugPLOS ONE
researchProduct

Construction of Group Exercise Sessions in Geriatric Inpatient Rehabilitation

2008

There is little knowledge about the ways geriatric physiotherapy is being carried out in practice and about the situational construction of formal policies for promoting physical activity. This article examines how professional physiotherapists and frail community-dwelling older adults as their clients use talk and action to construct a group exercise session in an inpatient rehabilitation setting in Finland. The analysis of 7 group exercise sessions with a total of 52 clients and 9 professional physiotherapists revealed 3 different practitioner approaches, which served different functions in older adults' empowerment and lifestyle activity change. The highly structured approach favored tac…

Malemedicine.medical_specialtyHealth (social science)medicine.medical_treatmentmedia_common.quotation_subjectsportsSession (web analytics)law.inventionNursingRandomized controlled triallawHumansMedicineSituational ethicsEmpowermentFinlandAgedmedia_commonAged 80 and overGeriatricsCircuit trainingInpatientsRehabilitationbusiness.industryCommunicationRehabilitationVideotape RecordingExercise TherapyGeriatricssports.sportFemalebusinessConstruct (philosophy)Health Communication
researchProduct

Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-[alpha]2b: A Randomized Trial

2009

BACKGROUND Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin. OBJECTIVE To evaluate use of peginterferon-alpha2a plus ribavirin to re-treat nonresponders to peginterferon-alpha2b plus ribavirin. DESIGN Randomized, parallel-group trial conducted between September 2003 and February 2007. Patients and researchers were not blinded to intervention assignment. Random assignment was centralized, computer-generated, and stratified by geographic region, hepatitis C virus (HCV) genotype, and histologic diagnosis. SETTING 106 international centers. PATIENTS 950 nonresponders to 12 or more weeks of therapy with peginterferon-alpha2b plus ribav…

Malemedicine.medical_specialtyHepatitis C virusAlpha interferonHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundDouble-Blind MethodRandomized controlled triallawPegylated interferonInternal medicineRibavirinInternal Medicineretreatment non responder hepatitis CHumansMedicineTreatment FailureNot evaluatedbusiness.industryRibavirinInterferon-alphavirus diseasesGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesSurgerychemistryRetreatmentRNA ViralDrug Therapy CombinationFemalebusinessViral loadmedicine.drug
researchProduct

Laparoscopic versus open mesh repair for recurrent inguinal hernia: a meta-analysis of outcomes

2009

Abstract Background The objective of this study was to examine the outcomes of comparisons between laparoscopic and open mesh repairs in the setting of recurrent inguinal hernia. Methods The electronic databases MEDLINE, Embase, Pubmed, and the Cochrane Library were used to search for articles from 1990 to 2008. The present meta-analysis pooled the effects of outcomes of a total of 1,542 patients enrolled into 5 randomized controlled trials and 7 comparative studies, using classic and modern meta-analytic methods. Results Significantly fewer cases of hematoma/seroma formation were observed in the laparoscopic group in comparison with the Lichtenstein group (odds ratio, .38; .15–.96; P = .04…

Malemedicine.medical_specialtyHernia InguinalCochrane Librarylaw.inventionRandomized controlled trialRecurrencelawmedicineHumansHerniaAgedbusiness.industryGeneral MedicineOdds ratioMiddle AgedSurgical Meshmedicine.diseaseSurgeryInguinal herniaTreatment OutcomeSurgical meshSeromaRelative riskFemaleLaparoscopySurgerybusinessThe American Journal of Surgery
researchProduct

Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification

2007

Multisystem Langerhans cell histiocytosis (MS-LCH) is associated with high mortality when patients have risk organ involvement (RO+) or are younger than 2 years. In an international randomized trial, LCH-II, we intensified their treatment: arm A consisted of 6 weeks of daily prednisone and weekly vinblastine followed by 18 weeks of daily 6-mercaptopurine with vinblastine/prednisone pulses; etoposide was added in arm B. Considering all 193 randomized risk patients, there were similar outcomes: rapid (6 weeks) response (arm A vs arm B: 63%/71%), 5-year survival probability (74%/79%), disease reactivation frequency (46%/46%), and permanent consequences (43%/37%). However, (1) patients younger …

Malemedicine.medical_specialtyImmunologyAdult Langerhans Cell HistiocytosisBiochemistryGastroenterologylaw.inventionLangerhans cell histiocytosisRandomized controlled trialRisk FactorsPrednisonelawInternal medicineHumansMedicineEtoposideDemographyHematologybusiness.industryInfantCell BiologyHematologymedicine.diseaseSurgeryVinblastineSurvival RateHistiocytosis Langerhans-CellTreatment OutcomeChild PreschoolOrgan involvementFemalebusinessmedicine.drugBlood
researchProduct

Influenza Vaccination After Myocardial Infarction:A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

2021

Background: Observational and small, randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease. Methods: We conducted an investigator-initiated, randomized, double-blind trial to compare inactivated influenza vaccine with saline placebo administered shortly after myocardial infarction (MI; 99.7% of patients) or high-risk stable coronary heart disease (0.3%). The primary end point was the composite of all-cause death, MI, or stent thrombosis at 12 months. A hierarchical testing strategy was used for the key secondary end points: all-cause death, cardiovascular death, MI, and stent thrombosis. Results: Because of the COV…

Malemedicine.medical_specialtyInfluenza vaccineMEDLINEMyocardial Infarction030204 cardiovascular system & hematologyPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawPhysiology (medical)Multicenter trialInternal medicineinfluenza vaccinesmedicineHumans030212 general & internal medicineMyocardial infarctionbusiness.industryMiddle Agedmedicine.disease3. Good healthVaccinationTreatment Outcomemyocardial infarctionInfluenza Vaccinesrandomized controlled trialObservational studyFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct